April 6th, 2010 - 09:30 GMT Merck Serono: Erbitux granted extended use in Japan for 1st-line treatment of mCRC Patients with KRAS wild-type tumors Approval of change in product information is based on the data of the Phase III CRYSTAL trial Read more
June 7th, 2009 - 06:52 GMT Interim Analysis of Long-Term Data with ONGLYZA™ (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Present
